Integrin Beta 3 Market Report Overview, Pipeline by Companies, Pharmaceutical Research, Analysis 2019

Posted on 2019-10-01 by Mark Hub in Pharmaceuticals // 0 Comments

Albany, USA, 2019-Oct-01 — /EPR Network/ —

Market Research Hub (MRH) has actively uploaded a smart research report titled “Integrin Beta 3-Pipeline Review, H2 2019”, to its broad online database. The primary motive of this study is to impart vital details associated to development of the Integrin Beta 3. The assessment includes brief knowledge about market size, Y-o-Y growth, market dynamics and competitive scenario expected to transform in the near future. Ever section of the report contains imperative market data that can prove useful for new entrants and industry players to draw crucial tactics.

Request Sample Report@ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2519501

Integrin Beta 3 – Pipeline Review, H2 2019

Summary

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) pipeline Target constitutes close to 24 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes. The latest report Integrin Beta 3 – Pipeline Review, H2 2019, outlays comprehensive information on the Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) – Integrin beta-3 (3) or CD61 is a protein that in humans is encoded by the ITGB3 gene. Integrin beta 3 is found along with the alpha IIb chain in platelets. It is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Willebrand factor. Activation of integrin alpha-IIb/beta-3 leads to platelet interaction through binding of soluble fibrinogen. This leads to rapid platelet aggregation which physically plugs ruptured endothelial surface.

The molecules developed by companies in Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 2, 1 and 15 respectively. Similarly, the universities portfolio in Preclinical stages comprises 5 molecules, respectively. Report covers products from therapy areas Oncology, Ophthalmology, Cardiovascular, Metabolic Disorders, Dermatology, Gastrointestinal, Infectious Disease, Central Nervous System and Immunology which include indications Wet (Neovascular / Exudative) Macular Degeneration, Breast Cancer, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Diabetic Macular Edema, Glioblastoma Multiforme (GBM), Metastatic Melanoma, Pancreatic Cancer, Persistent Corneal Epithelial Defects, Wounds, Diabetic Nephropathy, Diabetic Retinopathy, Escherichia Coli Septicaemia, Ischemic Stroke, Liver Cancer, Lung Cancer, Malabsorption Syndrome, Melanoma, Multiple Myeloma (Kahler Disease), Myocardial Infarction, Primary Sclerosing Cholangitis, Prostate Cancer, Relapsing Multiple Sclerosis (RMS), Rheumatoid Arthritis, Sepsis, Staphylococcus Aureus Septicaemia and Triple-Negative Breast Cancer (TNBC).

Furthermore, this report also reviews key players involved in Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Browse Complete Research Report with TOC@ https://www.marketresearchhub.com/report/integrin-beta-3-pipeline-review-h2-2019-report.html

Scope

– The report provides a snapshot of the global therapeutic landscape for Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3)
– The report reviews Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved in Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics and enlists all their major and minor projects
– The report assesses Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news and deals related to Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics

Reasons to buy

– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand the targeted therapy areas and indications for Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3)
– Identify the use of drugs for target identification and drug repurposing
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies
– Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) development landscape
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Make An Enquiry About This Report @ https://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=2519501

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports of different sector like pharmaceutical market research and analysis. MRH’s expansive collection of industry reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Matched content

Editor’s pick